| Autor: |
ŞAHİNGÖZ ERDAL, Gülçin, GÜLTÜRK, İlkay, ÖZMEN, Aykut, YILDIZ TACAR, Seher, YILMAZ, Mesut, TURAL, Deniz |
| Předmět: |
|
| Zdroj: |
Journal of Experimental & Clinical Medicine / Deneysel ve Klinik Tip Dergisi; Oct2022, Vol. 39 Issue 4, p1112-1119, 8p |
| Abstrakt: |
Despite all the advances in therapeutic modalities such as targeted therapies and immunotherapies that have recently been used in cancer treatment, Colorectal Cancer (CRC) continues to be the fourth most common cause of cancer-related deaths. The introduction of targeted monoclonal antibodies (mAbs) and their use in cancer treatment led to revolutionary advances in oncology. The aim of this study was to share our experiences regarding the usage rates of mAbs (Bevacizumab, Cetuximab, and Panitumumab), Overall Survival (OS) and progression-free survival (PFS) in patients with mCRC followed up in our hospital. This retrospective study included 210 patients with mCRC who were followed up in our hospital's oncology clinic between January 2010 and October 2020 and who received mAb treatment, regardless of their stage at the time of diagnosis. Fifty-two (24.8%) of the patients received a treatment regimen with Cetuximab and 46 with Panitumumab mAb. 29 patients (17.8%) received Cetuximab and Bevacizumab mAb treatment at different times, and 22 patients received Panitumumab and Bevacizumab mAb treatment, 112 of the patients received only Bevacizumab treatment. Panitumumab and Cetuximab mAb treatment was mostly taken in the 1st lines (69.6%, 76.9%, respectively). A statistically significant difference was found between the OSs of the cases according to the mAb treatment received (p = 0.001). Administration of Panitumumab and Cetuximab mAb in the 1st or 2nd series did not make a significant difference to PFS. When the retrospective data were evaluated, the distribution of Panitumumab and Cetuximab mAb treatments was seen to be balanced. Panitumumab and Cetuximab mAb therapy were not preferred for K-RAS mutant patients. They were preferred to give it in the first line. Patients who received anti EGFR mAb treatment had longer OS and PFS duration than those [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
